“The candidate is currently in phase II. Minerva also announced that it has completed enrolment in a randomized, placebo-controlled double-blind phase II trial on MIN-101 in Europe. Minerva is conducting the trial to evaluate the efficacy of MIN-101 compared to placebo in improving the symptoms of schizophrenic patients. This is also the primary endpoint of the trial. Other endpoints include the assessment of cognitive symptoms and overall symptomatology of the disease following treatment with MIN-101.”
2 Likes
is this for negative or cognitive symptoms of sz…???
its basically for negative symptoms ... along positive and cognitive..symptoms of sz..hope this will pass 2nd and 3rd phases trial...all eyes on min-101...
also see...
http://minervaneurosciences.com/
1 Like